IC
KALV

Ikarian Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Ikarian Capital’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-400,000
Closed -$4.87M – 201
2025
Q3 		$4.87M Hold
400,000
– – 0.49% 50
2025
Q2 		$4.52M Buy
+400,000
New +$4.89M 0.87% 35
2021
Q1 		– Sell
-145,500
Closed -$2.76M – 317
2020
Q4 		$2.76M Buy
+145,500
New +$2.5M 0.12% 137

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ikarian Capital's KALV Position: Q1 2026 in Review

Ikarian Capital held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 35,119 shares worth $707K. The position accounts for 0.06% of the portfolio, ranked #118.

Ikarian Capital first reported a position in KALV in Q4 2019 and has held it in 16 quarters since. The position peaked at $20.2M in Q4 2020. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Ikarian Capital held 35,119 shares of KalVista Pharmaceuticals worth $707K as of Q1 2026.
  • Ikarian Capital left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
  • KalVista Pharmaceuticals made up 0.06% of Ikarian Capital's portfolio in Q1 2026, its #118 holding.
  • Ikarian Capital first reported a position in KalVista Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
  • Ikarian Capital's KalVista Pharmaceuticals position peaked at $20.2M in Q4 2020.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.